20
Nov
2024
US-China Partnership: Just Hitting its Stride, and Now Threatened
Curon, Chimagen, Hengrui, LaNova…the list goes on of Chinese biotech companies that have recently licensed potential blockbuster drug candidates for cancer, autoimmunity and more to US pharma and biotech companies for further development. Over the past year or so, there has been a dramatic increase in both the number of deals to obtain rights to assets discovered in China, and... Read More